467 related articles for article (PubMed ID: 12507582)
21. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Quarta L; Cirulli N; Mancini L; Corrado A; Grassi FR; Grano M
J Pathol; 2007 May; 212(1):47-55. PubMed ID: 17370327
[TBL] [Abstract][Full Text] [Related]
22. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
Kubota A; Hasegawa K; Suguro T; Koshihara Y
J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
[TBL] [Abstract][Full Text] [Related]
24. Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor.
Chang K; Chang WH; Huang S; Huang S; Shih C
J Orthop Res; 2005 Nov; 23(6):1308-14. PubMed ID: 15913941
[TBL] [Abstract][Full Text] [Related]
25. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
Ren W; Li XH; Chen BD; Wooley PH
J Orthop Res; 2004 Jan; 22(1):21-9. PubMed ID: 14656655
[TBL] [Abstract][Full Text] [Related]
26. Osteoprotegerin and inflammation.
Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
[TBL] [Abstract][Full Text] [Related]
27. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
28. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer.
Lau YS; Danks L; Sun SG; Fox S; Sabokbar A; Harris A; Athanasou NA
Breast Cancer Res Treat; 2007 Sep; 105(1):7-16. PubMed ID: 17151927
[TBL] [Abstract][Full Text] [Related]
29. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
Abu-Amer Y; Abbas S; Hirayama T
J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
[TBL] [Abstract][Full Text] [Related]
30. Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin.
Hase H; Kanno Y; Kojima H; Sakurai D; Kobata T
Arthritis Rheum; 2008 Nov; 58(11):3356-65. PubMed ID: 18975335
[TBL] [Abstract][Full Text] [Related]
31. Osteoclast stimulating and differentiating factors in human cholesteatoma.
Hamzei M; Ventriglia G; Hagnia M; Antonopolous A; Bernal-Sprekelsen M; Dazert S; Hildmann H; Sudhoff H
Laryngoscope; 2003 Mar; 113(3):436-42. PubMed ID: 12616193
[TBL] [Abstract][Full Text] [Related]
32. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
33. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
Brage M; Lie A; Ransjö M; Kasprzykowski F; Kasprzykowska R; Abrahamson M; Grubb A; Lerner UH
Bone; 2004 Mar; 34(3):412-24. PubMed ID: 15003789
[TBL] [Abstract][Full Text] [Related]
34. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
35. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
[TBL] [Abstract][Full Text] [Related]
36. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
37. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
38. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
39. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Yamaguchi M; Uchiyama S
Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
[TBL] [Abstract][Full Text] [Related]
40. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
